重组人血小板活化因子乙酰水解酶治疗脑梗死的实验研究  

Study of recombinant human platelet activating factor acetylhydrolase for treatment of cerebral infarction

作　　者：张雄[1] 代成波[1] 吴宜娟[1] 王硕[1] 张玉虎[1] 马桂贤[1] 刘新通[1] 何池忠[1] 王丽娟[1] 

机构地区：[1]广东省人民医院神经内科广东省医学科学院广东省神经科学研究所,广州510080

出　　处：《中华老年心脑血管病杂志》2010年第10期943-946,共4页Chinese Journal of Geriatric Heart,Brain and Vessel Diseases

基　　金：广东省自然科学基金(8151008004000008)

摘　　要：目的观察重组人血小板活化因子乙酰水解酶(rPAF-AH)对大鼠脑梗死的治疗作用。方法 Wistar大鼠80只,采用分层随机法分为4组,空白组,模型组,rPAF AH组和银杏叶组,每组20只。后3组大鼠采用慢性动脉粥样硬化结合线栓法制成大鼠大脑中动脉闭塞脑梗死模型,观测各组大鼠神经行为学、脑梗死指数、血小板聚集率和血小板黏附率及5、15、30和60 min各时间点局部脑血流量(rCBF)变化,并进行比较。结果与空白组比较,模型组大鼠的神经行为学评分、脑梗死指数、血小板聚集率和血小板黏附率均明显升高(P<0.01);与模型组比较,除外银杏叶组血小板聚集率,rPAF-AH组和银杏叶组大鼠的神经行为学评分、脑梗死指数、血小板聚集率和血小板黏附率均明显降低(P<0.05),rPAF-AH组较银杏叶组血小板聚集率下降明显(P<0.05)。与空白组比较,模型组大鼠各时间点rCBF明显下降;与模型组比较,rCBF-AH组大鼠给药后各时间点,银杏叶组30和60 min时,rCBF不同程度升高(P<0.05)。结论 rPAF-AH对大鼠脑梗死具有明显的疗效,是一种值得期待的治疗脑梗死的生物医药制剂。Objective To observe the therapeutic effect of recombinant human platelet activating factor acetylhydrolase （rPAF-AH）on cerebral infarction in aged rats. Methods The cerebral ischemic model was established by nylon thread obstruction of the middle cerebral artery（MCAO） in atherosclerotic senile rats. After treatment with rPAF-AH and extract of Ginkgo biloba leaves injection,neurological deficit scores, index of cerebral infarction, aggregation and adhesion of platelets were determined. Cerebral blood flow（rCBF） was monitored by laser Doppler flowmeter. Results rPAF-AH obviously reduced neurological deficit scores,index of cerebral infarction, aggregation and adhesion of platelets,and improved rCBF in the brain after MCAO. Conclusion The rPAF-AH exerts a protective effect against cerebral ischemia injury,and may be a promising treatment for ischemic stroke.

关 键 词：1-烷基-2-乙酰甘油磷酸胆碱酯酶 脑梗死 动脉粥样硬化 血小板黏附 血小板聚集 

分 类 号：R743.33[医药卫生—神经病学与精神病学]